Thapar Nandita, Eid Mosab Ahmad Fathi, Raj Nishchita, Kantas Theodosios, Billing Harbir S, Sadhu Dhavalkumar
Manipal College of Medical Sciences, Pokhara, Kaski, Nepal.
Faculty of Medicine and Health Sciences, An-Najah National University, West Bank, Palestine.
Ann Med Surg (Lond). 2023 Nov 16;86(1):329-335. doi: 10.1097/MS9.0000000000001500. eCollection 2024 Jan.
The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas) nucleases system (CRISPR/Cas9) is a popular gene-editing technology with an expanding scope in the field of medicine. Recent studies have investigated the role of CRISPR/Cas9 system in the treatment of neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). Since the risk of occurrence of both conditions is strongly associated with genetic mutations and variations, the use of gene-editing technologies to rectify these genetic errors becomes relevant. The CRISPR/Cas9 system has been tested in AD, which has led to a decrease in either amyloid beta deposition or tau phosphorylation in cells. Likewise, genetic mutations in cells affected by PD have been corrected with promising results in initial studies undertaken. Therefore, the use of the CRISPR/Cas9 system should be expanded among different populations to understand its efficacy and safety in depth among neurodegenerative conditions.
成簇规律间隔短回文重复序列（CRISPR）/CRISPR相关（Cas）核酸酶系统（CRISPR/Cas9）是一种广受欢迎的基因编辑技术，在医学领域的应用范围不断扩大。最近的研究探讨了CRISPR/Cas9系统在治疗阿尔茨海默病（AD）和帕金森病（PD）等神经退行性疾病中的作用。由于这两种疾病的发病风险都与基因突变和变异密切相关，因此使用基因编辑技术纠正这些基因错误就变得很有意义。CRISPR/Cas9系统已在AD中进行了测试，这导致细胞中β淀粉样蛋白沉积或tau蛋白磷酸化减少。同样，在最初进行的研究中，受PD影响的细胞中的基因突变已得到纠正，取得了有希望的结果。因此，应在不同人群中扩大CRISPR/Cas9系统的使用，以深入了解其在神经退行性疾病中的疗效和安全性。
